Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept at the end of diabetic vitrectomy to prevent postoperative vitreous hemorrhage in proliferative diabetic retinopathy
ChiCTR1800015751Phase 4Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Apr 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of conbercept in diabetic retinopathy (DR) (2 arms), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoints: Incidence of vitreous hemorrhage after operation and Time of clearance of vitreous hemorrhage after operation. Started Apr 2018; status: recruiting.
02
Drugs
conbercept
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on ChiCTR1800015751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015751.